Effect of systemic medetomidine, an alpha 2 adrenoceptor agonist, on experimental pain in humans.
The effect of systemic (intravenous) medetomidine, an alpha-2 adrenoceptor agonist, on pain thresholds was studied in healthy human subjects (n = 6). Medetomidine produced a dose-dependent (cumulative doses: 25 and 50 micrograms) sedative effect evaluated by visual analog scale. Also, a dose-dependent decrease of blood pressure but not of heart rate was seen after administration of medetomidine. Pain threshold to electric stimulation of the tooth pulp and cutaneous heat pain threshold were uninfluenced by medetomidine. An index of cutaneous thermal sensitivity to innocuous stimuli, the width of the thermoneutral zone, also was uninfluenced by medetomidine. Medetomidine produced a significant attenuation of the affective-motivational component (unpleasantness) of tourniquet-induced ischemic pain, whereas the sensory-discriminative component (pain magnitude estimate) of the ischemic pain was not attenuated. The results suggest that systemic medetomidine alone at subanesthetic but sedative and hypotensive doses does not significantly influence the intensity and thresholds of experimental pain, whereas the affective-motivational component of pain can be attenuated.
Kauppila
T
T
Department of Physiology, University of Helsinki, Finland.
Kemppainen
P
P
Tanila
H
H
Pertovaara
A
A
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000328:Adult; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D020926:Medetomidine; D010146:Pain / Q000503:physiopathology*; D012684:Sensory Thresholds / Q000187:drug effects*
D000316:Adrenergic alpha-Agonists; D007093:Imidazoles; D020926:Medetomidine